Showing papers by "Miia Kivipelto published in 2001"
TL;DR: Raised systolic blood pressure and high serum cholesterol concentration, and in particular the combination of these risks, in midlife increase the risk of Alzheimer's disease in later life.
Abstract: Objective: To examine the relation of midlife raised blood pressure and serum cholesterol concentrations to Alzheimer9s disease in later life Design: Prospective, population based study Setting: Populations of Kuopio and Joensuu, eastern Finland Participants: Participants were derived from random, population based samples previously studied in a survey carried out in 1972, 1977, 1982, or 1987 After an average of 21 years9 follow up, a total of 1449 (73%) participants aged 65–79 took part in the re-examination in 1998 Main outcome measures: Midlife blood pressure and cholesterol concentrations and development of Alzheimer9s disease in later life Results: People with raised systolic blood pressure (≥160 mm Hg) or high serum cholesterol concentration (≥65 mmol/l) in midlife had a significantly higher risk of Alzheimer9s disease in later life, even after adjustment for age, body mass index, education, vascular events, smoking status, and alcohol consumption, than those with normal systolic blood pressure (odds ratio 23, 95% confidence interval 10 to 55) or serum cholesterol (odds ratio 21, 10 to 44) Participants with both of these risk factors in midlife had a significantly higher risk of developing Alzheimer9s disease than those with either of the risk factors alone (odds ratio 35, 16 to 79) Diastolic blood pressure in midlife had no significant effect on the risk of Alzheimer9s disease Conclusion: Raised systolic blood pressure and high serum cholesterol concentration, and in particular the combination of these risks, in midlife increase the risk of Alzheimer9s disease in later life What is already known on this topic Vascular risk factors may play an important part as risk factors for Alzheimer9s disease No population based studies have evaluated prospectively the impact of both midlife blood pressure and cholesterol concentration in both men and women on the subsequent development of Alzheimer9s disease What this study adds Raised systolic blood pressure and high serum cholesterol concentration, and in particular the combination of these risks, in midlife increased the risk of Alzheimer9s disease in later life Raised systolic blood pressure and hypercholesterolaemia may have a role in the pathogenesis of Alzheimer9s disease; more emphasis should be placed on identification and appropriate treatment of these conditions
1,534 citations
TL;DR: Data point to a role for midlife vascular risk factors in the development of MCI in late life, which has been considered as a predictor of AD.
Abstract: Objective: To evaluate the impact of midlife elevated serum cholesterol levels and blood pressure on the subsequent development of mild cognitive impairment (MCI) and to investigate the prevalence of MCI in elderly Finnish population, applying the MCI criteria devised by the Mayo Clinic Alzheimer’s Disease Research Center. Background: MCI has been considered as a predictor of AD. Vascular risk factors may be important in the development of cognitive impairment and AD. However, the role of vascular risk factors in MCI and the prevalence of MCI still remain virtually unknown. Methods: Subjects were derived from random, population-based samples previously studied in surveys carried out in 1972, 1977, 1982, and 1987. After an average follow-up of 21 years, 1,449 subjects aged 65 to 79 years were reexamined in 1998. Results: Eighty-two subjects, 6.1% of the population (average age, 72 years) met the criteria for MCI. Midlife elevated serum cholesterol level (≥6.5 mmol/L) was a significant risk factor for MCI (OR, 1.9; 95% CI, 1.2 to 3.0, adjusted for age and body mass index); the effect of systolic blood pressure approached significance. Conclusion: Data point to a role for midlife vascular risk factors in the development of MCI in late life.
724 citations
TL;DR: The APOE-ε4 allele may contribute to the unexplained weight loss in AD, especially in women, when men and women were analyzed separately, and weight loss was observed only in those women with AD with the ε4 allele.
Abstract: Objective: To investigate whether the APOE -e4 allele is associated with weight loss in patients with AD or in nondemented elderly subjects. Background: Weight loss has been considered a typical feature of AD. APOE -e4 is a risk factor for AD and was recently proposed to be associated with weight loss in elderly women. It is not known whether APOE- e4 is associated with weight loss in patients with AD or in the general population. Methods: Weight and BMI measurements at an average interval of 3.5 years and APOE phenotype determination were performed in an elderly population (n = 980), including 46 patients with AD and 911 control subjects at the end of the follow-up. Results: On average, patients with AD with the e4 allele lost 1.9 ± 4.0 kg (BMI 0.8 ± 1.8 kg/m 2 ) whereas e4 noncarriers gained 1.2 ± 3.8 kg (BMI 0.4 ± 1.5 kg/m 2 ) (both p p p Conclusions: The APOE -e4 allele may contribute to the unexplained weight loss in AD, especially in women.
49 citations